PharmaLundensis
0.20 SEK
-6.10 %
Less than 1K followers
PHAL
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for PharmaLundensis
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 1.31 | 0.81 | 0.91 | 0.71 | 0.45 | 0.61 | 0.25 |
| Shares | 28.3 | 28.3 | 31.9 | 33.9 | 42.6 | 51.0 | 60.0 |
| Market cap | 37.2 | 22.9 | 29.1 | 24.1 | 19.2 | 31.3 | 14.8 |
| Enterprise value | 37.9 | 25.8 | 32.4 | 28.4 | 21.8 | 35.8 | 18.3 |
| EV/S | - | - | - | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 6.07 | 7.78 | 9.11 | 13.67 | 6.06 | 9.50 | 5.14 |
| P/S | - | - | - | - | - | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 61.0 % | 38.5 % | 38.5 % | 20.1 % | 28.8 % | 32.8 % | 32.1 % |
| Gearing ratio | 32.7 % | 127.8 % | 130.7 % | 263.5 % | 163.0 % | 173.6 % | 164.5 % |